JP6535430B2 - 非定型プロテインキナーゼｃのアザキナゾリン阻害薬 - Google Patents

非定型プロテインキナーゼｃのアザキナゾリン阻害薬 Download PDF

Info

Publication number
JP6535430B2
JP6535430B2 JP2015534689A JP2015534689A JP6535430B2 JP 6535430 B2 JP6535430 B2 JP 6535430B2 JP 2015534689 A JP2015534689 A JP 2015534689A JP 2015534689 A JP2015534689 A JP 2015534689A JP 6535430 B2 JP6535430 B2 JP 6535430B2
Authority
JP
Japan
Prior art keywords
pyridin
pyrido
cyclopropyl
pyrimidin
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015534689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533822A5 (enExample
JP2015533822A (ja
Inventor
ブレスリン、ヘンリー、ジェイ．
ドーシー、ブルース、ディー．
デュガン、ベンジャミン、ジェイ．
ファウラー、キャサリン、エム．
ハドキンズ、ロバート、エル．
メサロス、オイゲン、エフ．
モンク、ナサニエル、ジェイティー
モリス、エマ、エル．
オロウォーイ、イケオルワ
オット、グレゴリー、アール．
ペイヴ、グレゴアール、エー．
ルーフェイ、ジョナサン、アール．エー．
サウディ、クリステル、エヌ．
タオ、ミン
ズィフィクサック、クレイグ、エー．
ズッリ、アリソン、エル．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2015533822A publication Critical patent/JP2015533822A/ja
Publication of JP2015533822A5 publication Critical patent/JP2015533822A5/ja
Application granted granted Critical
Publication of JP6535430B2 publication Critical patent/JP6535430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015534689A 2012-09-28 2013-09-27 非定型プロテインキナーゼｃのアザキナゾリン阻害薬 Active JP6535430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261707340P 2012-09-28 2012-09-28
US61/707,340 2012-09-28
US201361781364P 2013-03-14 2013-03-14
US61/781,364 2013-03-14
PCT/US2013/062085 WO2014052699A1 (en) 2012-09-28 2013-09-27 Azaquinazoline inhibitors of atypical protein kinase c

Publications (3)

Publication Number Publication Date
JP2015533822A JP2015533822A (ja) 2015-11-26
JP2015533822A5 JP2015533822A5 (enExample) 2017-06-22
JP6535430B2 true JP6535430B2 (ja) 2019-06-26

Family

ID=49326872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534689A Active JP6535430B2 (ja) 2012-09-28 2013-09-27 非定型プロテインキナーゼｃのアザキナゾリン阻害薬

Country Status (18)

Country Link
US (2) US9914730B2 (enExample)
EP (1) EP2900666B1 (enExample)
JP (1) JP6535430B2 (enExample)
KR (1) KR102215272B1 (enExample)
CN (1) CN105102456B (enExample)
AU (1) AU2013323360B2 (enExample)
BR (1) BR112015007061B1 (enExample)
CA (1) CA2886495C (enExample)
CL (1) CL2015000781A1 (enExample)
EA (1) EA030253B1 (enExample)
IL (1) IL237918B (enExample)
MX (1) MX372736B (enExample)
NZ (1) NZ706857A (enExample)
PH (1) PH12015500689A1 (enExample)
SG (1) SG11201502301YA (enExample)
TW (1) TWI663165B (enExample)
WO (1) WO2014052699A1 (enExample)
ZA (1) ZA201502783B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX372736B (es) * 2012-09-28 2020-06-19 Cancer Research Tech Ltd Inhibidores de azaquinazolina de la proteina quinasa c atipica.
JP6391120B2 (ja) 2012-12-20 2018-09-19 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体１の小分子アゴニスト
GEP201706780B (en) 2013-03-14 2017-11-27 Boehringer Ingelheim Int Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ718190A (en) 2013-08-23 2017-10-27 Neupharma Inc Substituted quinazolines for inhibiting kinase activity
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
WO2015200534A2 (en) 2014-06-25 2015-12-30 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016037106A1 (en) * 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
SG11201702075QA (en) * 2014-10-29 2017-04-27 Dong A St Co Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CN105288512A (zh) * 2015-12-08 2016-02-03 李野林 一种治疗肥胖症的中药组合物
ES2993451T3 (en) 2016-06-13 2024-12-30 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
AU2017312561B2 (en) * 2016-08-15 2022-06-30 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2017312970B2 (en) * 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
WO2018051306A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
KR102563325B1 (ko) 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
WO2019001572A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
KR102603203B1 (ko) 2018-07-25 2023-11-16 파에스 파마, 에스.에이. 히스타민 h4-수용체 저해제로서 피리도피리미딘류
EP3831823A4 (en) * 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
JP7603605B2 (ja) * 2019-03-28 2024-12-20 キャンサー・リサーチ・テクノロジー・リミテッド 非定型プロテインキナーゼｃの阻害剤およびヘッジホッグ経路依存性癌の治療におけるその使用
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
CN116120243B (zh) * 2021-11-15 2025-07-29 都创(上海)医药科技股份有限公司 aPKC抑制剂化合物中间体片段及其制备方法和应用
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法
CN117088898B (zh) * 2022-05-13 2026-02-06 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
CN120882714A (zh) * 2022-12-13 2025-10-31 风树疗法公司 {5-环丙基-2-[2-(3,6-二氟-吡啶-2-基氨基)-吡啶-4-基]-吡啶并[3,4-d]嘧啶-4-基}-((s)-3,3-二甲基-哌啶-4-基)-胺的固体形式
CN117343005A (zh) * 2023-10-08 2024-01-05 上海泰坦科技股份有限公司 一种异烟酸衍生物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (enExample) 1972-08-16 1974-04-05
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002080423A (ja) * 2000-09-06 2002-03-19 Daikin Ind Ltd トリフルオロ酢酸エチルの合成方法
DK1318997T3 (da) * 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008531538A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
AU2007287430B2 (en) * 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
RU2009108006A (ru) * 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
US8993552B2 (en) * 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
MX372736B (es) * 2012-09-28 2020-06-19 Cancer Research Tech Ltd Inhibidores de azaquinazolina de la proteina quinasa c atipica.
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016040330A1 (en) * 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
KR20180103053A (ko) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제

Also Published As

Publication number Publication date
PH12015500689B1 (en) 2015-05-25
MX2015004016A (es) 2016-02-18
KR20150086248A (ko) 2015-07-27
IL237918A0 (en) 2015-05-31
KR102215272B1 (ko) 2021-02-15
NZ706857A (en) 2018-05-25
US9896446B2 (en) 2018-02-20
BR112015007061A2 (pt) 2017-07-04
HK1211928A1 (en) 2016-06-03
MX372736B (es) 2020-06-19
IL237918B (en) 2021-05-31
PH12015500689A1 (en) 2015-05-25
ZA201502783B (en) 2016-01-27
US9914730B2 (en) 2018-03-13
AU2013323360B2 (en) 2017-09-07
US20140113882A1 (en) 2014-04-24
BR112015007061B1 (pt) 2022-10-04
WO2014052699A9 (en) 2015-07-16
CN105102456B (zh) 2017-11-14
CA2886495A1 (en) 2014-04-03
HK1212336A1 (en) 2016-06-10
CA2886495C (en) 2023-09-19
SG11201502301YA (en) 2015-04-29
CL2015000781A1 (es) 2016-04-01
EA030253B1 (ru) 2018-07-31
CN105102456A (zh) 2015-11-25
TWI663165B (zh) 2019-06-21
AU2013323360A1 (en) 2015-04-30
BR112015007061A8 (pt) 2019-08-20
EA201590661A1 (ru) 2015-09-30
JP2015533822A (ja) 2015-11-26
WO2014052699A1 (en) 2014-04-03
EP2900666B1 (en) 2020-11-04
EP2900666A1 (en) 2015-08-05
US20160102094A1 (en) 2016-04-14
TW201427978A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
JP6535430B2 (ja) 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
EP3152210B1 (en) Tank-binding kinase inhibitor compounds
US10414763B2 (en) Azaquinazoline inhibitors of atypical protein kinase C
CN119546604A (zh) 作为hpk1抑制剂的吡啶并[3,2-d]嘧啶
HK1212336B (en) Azaquinazoline inhibitors of atypical protein kinase c
HK1211928B (en) Azaquinazoline inhibitors of atypical protein kinase c
HK1236197A1 (en) Tank-binding kinase inhibitor compounds
HK1236197B (en) Tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190601

R150 Certificate of patent or registration of utility model

Ref document number: 6535430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250